Fig. 1
From: Medical treatment of mammary desmoid-type fibromatosis: which benefit?
Tumor evolution on MRI. a–c MRIs during tamoxifen + arthrocine association (tumoral volume respectively 27.4, 27.1, and 30.4 cm3). d–f MRIs during sorafenib (tumoral volume respectively 24.7, 26.5, and 25.6 cm3). g MRI during IFN (tumoral volume 26.4 cm3). h, i MRIs during sunitinib (tumoral volumes respectively 15.3 and 13.2 cm3)